Lyra Therapeutics (LYRA) Income towards Parent Company (2021 - 2025)
Historic Income towards Parent Company for Lyra Therapeutics (LYRA) over the last 5 years, with Q3 2025 value amounting to -$6.0 million.
- Lyra Therapeutics' Income towards Parent Company rose 4959.99% to -$6.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$32.9 million, marking a year-over-year increase of 6624.7%. This contributed to the annual value of -$93.4 million for FY2024, which is 4906.67% down from last year.
- Lyra Therapeutics' Income towards Parent Company amounted to -$6.0 million in Q3 2025, which was up 4959.99% from -$7.4 million recorded in Q2 2025.
- Over the past 5 years, Lyra Therapeutics' Income towards Parent Company peaked at -$6.0 million during Q3 2025, and registered a low of -$48.1 million during Q2 2024.
- Moreover, its 5-year median value for Income towards Parent Company was -$13.6 million (2021), whereas its average is -$14.6 million.
- Its Income towards Parent Company has fluctuated over the past 5 years, first plummeted by 20817.65% in 2024, then soared by 8454.84% in 2025.
- Lyra Therapeutics' Income towards Parent Company (Quarter) stood at -$13.6 million in 2021, then decreased by 4.44% to -$14.2 million in 2022, then fell by 6.57% to -$15.2 million in 2023, then increased by 27.56% to -$11.0 million in 2024, then surged by 45.5% to -$6.0 million in 2025.
- Its Income towards Parent Company was -$6.0 million in Q3 2025, compared to -$7.4 million in Q2 2025 and -$8.5 million in Q1 2025.